Insufficient basis for the inclusion of Human papillomavirus vaccination in the National Immunisation Programme in the Netherlands;Onvoldoende gronden voor opname van vaccinatie tegen Humaan papillomavirus in het Rijksvaccinatieprogramma

Nederlands Tijdschrift voor Geneeskunde

Volumn 152, Issue 37, 2008, Pages 2001-2004

  De Kok, I M C M ^a   Habbema, J D F ^a   Mourits, M J E ^b   Coebergh, J W W ^a   Van Leeuwen, F E ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

DRUG EFFICACY; FOLLOW UP; HEALTH CARE ORGANIZATION; HEALTH PROGRAM; HUMAN; IMMUNIZATION; NETHERLANDS; NOTE; PATIENT SAFETY; PUBLIC HEALTH; SCREENING; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS;

ADOLESCENT; CHILD; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; NETHERLANDS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 52249111597     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (10)

1. Vaccinatie tegen baarmoederhalskanker. Den Haag: Gezondheidsraad; 2008.
2. Rossum TGJ van, Melker HE de, Houweling H, Voordouw ACG, Meijer CJLM, Helmerhorst ThJM, et al. Vaccins tegen Humaan papillomavirus (HPV); tussen registratie en implementatie. Ned Tijdschr Geneeskd. 2008;152:987-92.
3. Rebolj M, Ballegooijen M van, Berkers LM, Habbema D. Monitoring a national cancer prevention program: successful changes in cervical cancer screening in the Netherlands. Int J Cancer. 2007;120:806-12.
4. Aa MA van der, Pukkala E, Coebergh JW, Anttila A, Siesling S. Mass screening programmes and trends in cervical cancer in Finland and the Netherlands. Int J Cancer. 2008;122:1854-8.
5. Aa MA van der, Schutter EM, Looijen-Salamon M, Martens JE, Siesling S. Differences in screening history, tumour characteristics and survival between women with screen-detected versus not screen-detected cervical cancer in the east of the Netherlands, 1992-2001. Eur J Obstet Gynecol Reprod Biol. 2008;139:204-9.
6. Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007;369:1861-8.
7. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2006;107:18-27.
8. Oortmarssen GJ van, Habbema JD. Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer. Br J Cancer. 1991;64:559-65.
9. Clifford G, Franceschi S, Diaz M, Muñoz N, Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine. 2006;24 Suppl 3:826-34.
10. Signaleringscommissie Kanker van KWF Rankerbestrijding. Vroege opsporing van dikkedarmkanker. Amsterdam: Nederlandse Rankerbestrijding/Koningin Wilhelmina Fonds; 2004.